

CURRICULUM VITAE

Name: David Seth Feldman, MD/PhD, FACC 2006

Current Position: Director of Heart Failure and Cardiac Transplantation
Director of Heart Failure and Transplant Fellowship Program
Assistant Professor of Medicine and Cardiology
Assistant Professor of Physiology and Cell Biology
The Ohio State University Medical Center

Office Address: Suite 200, Davis Heart and Lung Research Institute
473 West 12th Avenue
Columbus, OH 43210-1252
Office 614-247-7754
Fax 614-247-7755
Beeper # 614-346-2123
Email; david.feldman@osumc.edu

Previous Positions:

2001-2003 Assistant Professor of Medicine and Cardiology
Section of Heart failure and Cardiac Transplantation
Medical University of South Carolina

Post-Graduate Training:

1999-01 Associate of Medicine (Instructor)
Duke University Medical Center and
The Howard Hughes Medical Institute
Durham, North Carolina
Research Co-mentors: Robert Lefkowitz and Louis
Luttrell

1997-99 Cardiology Fellow, Barnes-Jewish Hospital
Washington University School of Medicine
St. Louis, Missouri
Additional Training in Heart Failure and Cardiac
Transplantation

1995-97 Internal Medicine Residency, Barnes Hospital
Washington University School of Medicine
St. Louis, Missouri

1995 Instructor, Departments of Neurology and
Pharmacology
Medical College of Georgia, Augusta, Georgia

Education:

- 1988-94 Doctorate of Philosophy and Medicine (M.D./Ph.D.)
Medical College of Georgia
Augusta, Georgia
Research Mentor- Jerry Buccafusco
- 1987-88 Graduate Education (Neuroscience and Medicine)
New York University
New York, New York
- 1983-86 Bachelor of Arts (Biology and Psychology)
Emory University
Atlanta, Georgia

Additional Professional Experience:

- 2000-01 Hospitalist/Cardiologist- Night Call
Rex Hospital
(Affiliate of The University of North Carolina)
Raleigh, North Carolina
- 1997-99 Intensive Care Fellow - Night Call
Bone Marrow Transplant Unit, Barnes Hospital
St. Louis, Missouri
- 1997 Guest Registrar-Cardiology
Mater Misericordiae Hospital, University College of
Medicine
Dublin, Ireland
- 1990-94 Graduate Research Assistant, Dept. of Pharmacology
Medical College of Georgia
Augusta, Georgia
- 1989-92 Clinical Extern, Dept. of Anesthesiology
Medical College of Georgia
Augusta, Georgia
- 1987-88 Graduate Research Assistant, Dept. of Neuroscience
New York University
New York, New York

(Additional Professional Experience)

- 1985 Research Assistant, Dept. of Biology
Emory University
Atlanta, Georgia
- 1983-86 Medical Laboratory Technician
Roche Biomedical Laboratory

Teaching Experience:

- 2003-P Coordinator for Cardiology Fellowship Board Review
The Ohio State University Medical Center
- 2003-P Selected Medical Student Lectures
The Ohio State University Medical Center
- 2003-P Selected Lectures for Internal Medicine and
Emergency Medicine House Staff/Morning Report
- 2003-P Heart Failure and General Cardiology
Preceptor for Post-doctoral PharmD Students
(9 month commitment)
- 2001-03 Selected Lectures Cardiology and Pulmonary/Critical
Care Fellows, Medical University of South Carolina
- 1998-03 Selected Heart Failure Lectures and Cardiology
Physician Assistants Program and School of Nursing
- 1997-P Selected Lectures, Advanced Cardiac Life Support
American Heart Association Certification Course
- 1991-95 Selected Lectures and Labs in Clinical Pharmacology
Medical College of Georgia School of Medicine
- 1991-95 Selected Lectures in Physical Diagnosis
Medical College of Georgia School of Medicine
- 1986-87 High School Biology Teacher
Fulton County Board of Education
Atlanta, Georgia

Honors:

- * Fellow of American College of Cardiology
- * Cardiology Faculty-Teacher of the Year Award, MUSC 2003
- * Alpha Omega Alpha (AOA)
- * Sigma Xi (Honor Society, Graduate School)
- * Maxwell Scholar, Medical College of Georgia, 1989-94
- * Pfizer Presentation Award, Association of Pharmacology and Therapeutics, 1992
- * Science and Community Award, Sigma Xi, 1992
- * Gallatin Scholar, New York University, 1987
- * Faculty Merit Scholar, Emory University, 1984-86

Professional Societies:

- * American Heart Association (AHA)
- * American College of Physician (ACP)
- * American College of Cardiology (ACC)
- * Heart Failure Society of America (HFSA)
- * International Society of Heart and Lung Transplantation (ISHLT)

University Leadership and Committees:

- * OSU, Congestive Heart Failure Guidelines Implementation Committee,
- * OSU, Computer and Communications Committee for The Ross Cardiac Hospital
- * OSU, Fellowship and Guidelines Committee
- * OSU, Outcomes Committee for The Ohio State University
- * Pharmacy and Therapeutics Committee, MUSC 2003
- * Internal Medicine Selection Committee, MUSC 2001-03
- * Informatics Committee, Cardiology Division, MUSC 2001
- * Barnes Coronary Care Unit Quality Control Committee, 1996
- * Barnes Housestaff Liaison Committee, 1995-96

- * Liaison Committee for Medical Education, Medical College of Georgia,
- * Secretary/Treasurer, Medical College of Georgia, Class of 1992
- * Chief Extern, Department of Anesthesiology, 1990-92
- * National Representative for MD/PhD Program, Medical College of Georgia.

Extramural Leadership and Committees:

- * Reviewer for Journal of American College of Cardiology
- * Reviewer for Chest
- * Reviewer for Journal of Cardiac Failure
- * Reviewer for Life Sciences
- * Reviewer for Journal of Congestive Heart Failure
- * Reviewer for Circulation
- * Reviewer for American Journal of Medicine
- * Reviewer for the American Journal of Cardiology
- * Member of Heart Failure Society of America Leadership Research Council (1 of 8 in the country, elected)
- * Abstract Reviewer for International Heart and Lung Transplantation Society 2003-06.
- * Abstract Reviewer for American College of Cardiology 2006
- * Lecturer for American College of Physicians, Ohio, Cardiology MKSAP

Board Certification:

- * American Board of Internal Medicine; Cardiovascular Medicine Boards
- * American Board of Internal Medicine; Internal Medicine Boards
- * Advanced Cardiac Life Support Instructor, American Heart Association
- * Current Ohio, Missouri, North Carolina, and South Carolina State Medical Licenses
- * Active DEA #
- * National Board Medical Exams Parts I, II and III
- * Teaching Certificate, Special Education and Science, Atlanta, Georgia

Participation in Clinical Trials:

1. Phase II trial evaluating Efficacy and Safety of YM087, Vasopressin Antagonist, PI.
2. Phase II trial evaluating Efficacy and Safety of MCC135, PI.
3. Compass Trial ; Phase III trial evaluating Efficacy of new HF device, PI
4. REVERSE Trial: Phase III trial evaluating the ability for CRT to decrease pathological Remodeling, PI.
5. CHRISTINA Trial: Phase IIIb trial evaluating mechanisms in the cardio-renal syndrome, National PI.
6. MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the ENhanced Treatment of CHF Unresponsive to Medical Therapy Orqis Medica, CoPI.
7. SALT OPEN LABEL: International, Multicenter, Study of One-Year, Open-Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatremia, CoPI.
8. Paracor Ventricular Support System. Paracor_Medical Inc., CoPI.
9. COREG 3 6 9: SK&F-105517/369: An Open, Nonrandomized Comparison of Pharmacokinetic profiles of Carvedilol (SK&F-105517) MR and IR on Repeat Dosing in Chronic CHF Patients and Survivors of an Acute MI and LVD, CoPI.
10. UNLOAD Trial: Ultrafiltration versus IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure: A Prospective Randomized Clinical Trial, CoPI.
11. IGMA-TAU: Safety and Tolerability of IV PSA 2744 in Adults with Chronic Heart Failure: A Phase I/II Study, CoPI.
12. FUSION II: Follow-up Serial Infusions of Natreacor (nesiritide) for the Management of Patients with Heart Failure, CoPI.
13. PROSPECT: Predictors of Response to Cardiac Resynchronization Therapy, CoPI.
14. ORQIS OBSERVATIONAL: A Multi-Center, Observational Study of Patients with Severe Heart Failure, CoPI.
15. FIX-HF-5 (Phase I & II): Evaluation of the Safety and Efficacy of the Optimizer II System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction, CoPI.

16. EMPOWER (MY-023-E) Study: An Open-Label Enoximone Extension Study for Subjects Who Clinically Deteriorate Following Withdrawal of Enoximone in EMPOWER (My-023). Myogen. CoPI.
17. THE REVIVE STUDY: Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure, CoPI.
18. A Phase III, Randomized, double blind, multi-center, parallel group, placebo controlled stud of oral Enoximone vs placebo on advanced chronic heart failure subjects, CoPI.
19. Diuretic Synergy 704-.351: Evaluation of Synergy Between Natreacor and Furosemide on Renal and Neurohormone Responses in Chronic Heart Failure: A Phase IV Study, CoPI.
20. OPTION: Clinical Protocol for the option of CRT/Tx Clinical Investigation of CRT and Afib, CoPI.
21. Phase III trial, Prospect Trial - Primary Investigator
22. Phase III trial, Chronicle ICD, and OptiVol trials – Co-investigator
23. Phase IV survival trial, Bridge to Transplant (TMAC) inotrope and vasodilator vs. conventional medical therapy- Primary Investigator.

Publications:

Referred Manuscripts

1. Feldman, DS, Buccafusco, JJ: Localization of cholinergic neurons involved in the cardiovascular response to intrathecal injection of carbachol. *European Journal of Pharmacology*. 250:483-487, 1993.
2. Feldman, DS, Terry, AV, and Buccafusco, JJ: Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation. *European Journal of Pharmacology*. 313:211-220, 1996.
3. Feldman, DS, Buccafusco, JJ: Cholinergic and glutamatergic neuronal modulation in bulbospinal regulation. *Journal of Pharmacology and Experimental Therapeutics (JPET)*. 281:274-283, 1997.
4. Feldman, DS, Zamah, AM., Pierce, K., Miller, WE., Kelly, F., K., Koch, W., Rapacciuolo, A., Rockman, H., Lefkowitz, R.J., Luttrell, L. Selective inhibition of heterotrimeric G α s signaling: targeting the receptor-G protein

- interface using a peptide minigene to encode the G α s-carboxy terminus. *Journal of Biological Chemistry (JBC)*. 277(32): 28631-28640, 2002.
5. Walker, J.K., Gainetdinov R.R, Feldman, D.S., McFawn, P.K., Caron, M.G., Lefkowitz, R.J., Premont, R.T., Fisher, J.T. G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation. *American Journal of Physiology; Lung and Cell Molecular Pysiology (Am. J. physiol.)* 286:L312-L319, 2004.
 6. Feldman, D.S., Ikonomidis, J.S., Uber, W.E., Van Bakel, A.B., Piereira, N.L., Crumbley, A.J., Tann, S.M.: Human B-Natriuretic Peptide Improves Hemodynamics and Renal Function in Heart Transplant Patients Immediately After Surgery. *The Journal of Cardiac Failure* 10 (4): 292-296, 2004.
 7. Iyengar S, Feldman DS, Trupp R, Abraham WT. Nesiritide for the treatment of congestive heart failure. *Expert Opinion*; 5 (4); 901-907, 2004.
 8. Uber WE, Uber LA, Vanbakel AB, Cumbley AJ, Pereira NL, Ikonomidis JS, Feldman DS. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. *Transplant Proc.* 36 (10), 3245, 2004.
 9. Feldman DS, Sun B. Peri-operative management of heart failure utilizing Human B-Natriuretic Peptide. *Heart Fail Rev* ; 9 (3). 203, 2005.
 10. Peura JL, Zile MR, Feldman DS, VanBakel AB, McClure C, Uber W, Haynes H, Pereira NL. Effects of conversion of cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. *J Heart Lung Transplant* 24 (11): 1969-1972, 2005.
 11. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Beta-adrenergic receptors; alterations in signal transduction and pharmacogenomics in heart failure. *Nature; Clinical Practice Cardiovascular Medicine*; 2 (9); 475-483, 2005.
 12. Nishijima Y, Feldman DS, Bonagura J, Ozkanlar Y, Jenkins PJ, Abraham WT, Hamlin RL, Carnes CA. Canine nonischemic Left Ventricular Dysfunction: A Model of Chronic Human Cardiomyopathy. *J Card Failure* 11 (8): 638-644; 2005.
 13. Siachos T, VanBakel A, Feldman DS, Uber W, Simpson K, Pereira N. Silent Stroke in Patients with Heart Failure. *J Card. Failure* 11 (7): 485-489; 2005.
 14. Kubalova Z, Terentyev D, Viatchenko-Karpinski S, Nishijima Y, Terentyeva R, Sridhar A, Feldman DS, Hamlin RL, Carnes CC, Gyorke S.

- Abnormal intra-store calcium signaling in chronic heart failure. *Proceeding of National Academy of Science* 102 (39): 14104-14109; 2005.
15. Montgomery SS, Burke EM, Wissman SA, Feldman DS, Leier CV. Natural course of large spontaneous pneumothorax. *Heart Lung* 34(5): 332-334; 2005.
 16. Mehta R, Feldman D. Acute decompensated heart failure; best evidence and current practice. *Minerva Cardioangiol* 53: 537-547; 2005.
 17. Tein MH, Singh AK, Dasta JF, Feldman DS, Mebezza A. Contemporary issues in the pharmacologic management of acute heart failure. *Crit Care Clin* 22; 199-219. 2006.
 18. Wexler R, Feldman DS. Hypertension: which drugs to choose for patients with cardiovascular disease. *J Fam Pract* 55 (4), 291-298, 2006.
 19. Feldman, D. Timing for transplant; superior genetics or social prejudice. *JACC* 47, 2243-4, 2006.
 20. Iyenger S, Feldman DS, Cooke G, Leier CV, Raman S. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. *J Heart Lung Transplant ;in press*, 2006.

Relevant Recent Book Chapters:

Dorman H, Feldman DS, Reves J. Agents Used to Treat Myocardial Ischemia. *Anesthetic Pharmacology: Physiologic principles and clinical practice*, Chapter 36 (Evers, A., Maze M., editors) 2004.

Feldman DS, Spinale FG. Extra-cellular Remodeling in Heart Failure; Potential Use of Matrix Metalloproteinase Inhibitors in Heart Failure: Practical guide to the management of heart failure, Chapter 15 (Yancy C, Young J, editors) due out for AHA 2006.

Farroni J, Feldman DS, Paul S. How to Develop a Heart Failure Management Pathway; *Heart failure: a practical approach to therapy*, Chapter 19 (Abraham WT, Krum H, editors) due out for ACC 2007.

Invited Publications, Editor Reviewed

1. From Bench to Bedside, Nature Vol 424: 1090-1091, 2003.
2. University of Minnesota Continual Medical Education, Commentary on the COMET Trail, 2003.
3. Review of Heart News Letters for the General Public. Real Simple, 2005.

Published Abstracts (selected from Peer-Review only)

1. Feldman, DS, Buccafusco, JJ: Role of medullary cholinergic pressor neurons in the pressor response to spinal cholinergic stimulation. FASEB Journal. 4:A742, 1991.
2. Feldman, DS, Buccafusco, JJ: Putative role for an ascending cholinergic pathway in response to spinal cholinergic stimulation. Sixth Annual Medical Scientist Conference. 1:3, 1991.
3. Feldman, DS, Buccafusco, JJ: Role of NMDA receptors and nitric oxide synthase to spinal cholinergic stimulation. The Pharmacologist. 34(3):171, 1992.
4. Feldman, DS, Buccafusco, JJ: Role of NMDA receptors and nitric oxide on the pressor response to spinal cholinergic stimulation. 23 Congress of the International Union Physiological Society (Glasgow Scotland). 23:61, 1993.
5. Feldman, DS, Buccafusco, JJ: Role of glutamate and nitric oxide on the pressor response to spinal cholinergic stimulation in freely moving rats. Neuroscience. 19:313, 1993.
6. Feldman, D.S., Esposito, G., Lin, F., Mao, L., Lefkowitz, R.J., and Rockman, H.A.: β arrestin2 gene deletion attenuates pressure overload hypertrophy. Circulation. 102 (18): 121, 2000.
7. Walker, J.K.L., McFawn, P.K., Feldman, D.S., Gainetdinov, R.R., Caron, M.G., Lefkowitz, R.J., Premont, R.T., Fisher, J.T.: GRK5 regulates airway tone and cardiac chronotropy in mice. FASEB Journal. 15(4): A102, 2001.

8. Tann, S., Uber, W., VanBakel, A.B., Pereria, N.L., Crumbley, A.J., Ikonomidis, J.S., Feldman DS.: Nesiritide as an adjunct to the treatment of decompensated heart failure immediately after cardiac transplantation. *American Journal of Transplantation*, Supplement 3 (Vol. 2): 316, 2002.
9. Siachos, A.T., VanBakel, A.B., Crumbley, A.J., Feldman, D.S., Ikonomidis, J., Uber, W., Simpson, K., Pereira, N.L., Silent cerebral infarction in patients with dilated cardiomyopathy being evaluated for heart transplantation. *Journal of Cardiac Failure*, Supplement 4 (Vol. 8): S77, 2002.
10. Siachos, A.T., VanBakel, A.B., Feldman, D.S., Uber, W., Simpson, K., Pereira, N.L., Race as a risk factor for silent cerebral infarction in patients with dilated cardiomyopathy being evaluated for heart transplantation. *Circulation* (Vol. 106, 16): 13, 2002.
11. Tann, S.M., Ikonomidis, J.S., Uber, W., VanBakel, A.B., Pereria, N.L., Crumbley, A., Feldman, D.S., B-Natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. *The Journal of Heart and Lung Transplantation* (Vol. 22, 1S): 257, 2003.
12. Uber, W.E., Padgett, S.L., VanBakel, A.B., Crumbley, A.J., Feldman, D.S., Ikonomidis, J.S., Simpson, K.N., Pereira, N.L. Predictors and outcomes of acute humeral rejection treated with plasmapheresis in heart transplant recipients. *The Journal of Heart and Lung Transplantation* (Vol. 22, 1S): 294, 2003.
13. Tann, S.M., Nielsen, C., Killip, D., Feldman, D.S., Spencer III, W.H., B-type natriuretic peptide levels in patients with hypertrophic cardiomyopathy treated with alcohol spetal ablation. *Journal of Amercian College of Cardiology* (Vol 41, number 6): 144, 2003.
14. Uber W.E., Uber L.A., VanBakel A.B., Crumbley A.J., Pereira N.L., Ikonomidis J.S., Feldman D.S. Outcomes of CD3 monitoring with Thymoglobulin therapy in cardiac transplantation. *American Journal of Transplantation*, Supplement 4 (Vol. 3): 381, 2003.
15. Peura J., Feldman D.S., VanBakel A.B, Zile M., Pereira N.L., Alterations in left ventricular remodeling in post transplant patients. *Circulation*. 108 (17): 330-331, 2003.
16. Carnes CA, Nishijima Y, Jenkins P, da Cunha D, Abraham WT, Feldman DS, Hamlin RL. Left ventricular dysfunction and impaired exercise tolerance in a chronic canine model. *Journal of Cardiac Failure* (vol. 10, number 4 supplement):S37, 2004

17. Nicholson D, Haas GJ, Carnes CA, Abraham WT, Feldman DS. Lack of efficacy of N-acetylcysteine in attenuating contrast induced nephropathy in patients with severe systolic heart failure. *Journal of Cardiac Failure* (vol. 10, number 4 supplement):S131, 2004.
18. Carnes CC, Nishijima Y, Da Cunha D, Feldman DS, Hamlin RL, Bonagura J. Chronic right ventricular tachypacing results in QRS prolongation and left ventricular dysfunction and dyssynchrony. *Heart Rhythm* (2, 1S), S180, 2005.
19. Alam M, Silber D, Mullen M, Brown R, Yancy C, Feldman D, Oren R, Kirklin J. Cutaneous malignancies after cardiac transplant. *The Journal of Heart and Lung Transplantation* (Vol. 24, 2S): S16, 2005.
20. Feldman DS, Biniakiewicz D, Leier CV. Society's self-imposed standards infringe on personal liberty and markedly reduce availability of donor organs; a case for self-directed heart donation. *The Journal of Heart and Lung Transplantation* (Vol. 24, 2S): S127, 2005.
21. Feldman D, Dasta J, McLaughlin T, Padley R, Durtschi. Comparison of patients with primary vs secondary heart failure from a database of 2.5 million admissions: Implications for coding and reimbursement policies. *Circulation*;111:e345, 2005.
22. Dasta J, Durtschi A, Padley R, Feldman D. The development of a database of patients admitted with primary and secondary heart failure from 2.5 million admissions: patient characteristics and outcomes. *J Cardiac Failure*, 11, 2005.
23. Dasta J, Ng T, Durtschi A, McLaughlin T, Feldman D. Cost analysis of patients with acute heart failure: Characteristics and outcomes of high vs. low cost groups. *Pharmacotherapy* 2005.
24. Moazami N, Brown RN, Kirklin JK, Aaronson K, VanBakel AB, Lewis N, Feldman DS, Oren RN, Krull J. Effects of high potassium heart transplant preservation solutions on the development of cardiac allograft vasculopathy ; a multi-institutional investigation. *J of heart and lung transplant* 25; S116, 2006.
25. Ng MT, Dasta JF, Durtschi AJ, McLaughlin T, Feldman D. Cost analysis and outcomes of hospitalized patients with a secondary diagnosis of heart failure. *J Cardiac Failure*, 12;322, 2006.
26. Biophysics 2006 (two abstracts)
27. American Heart Association (three abstracts)

Invited Presentations (selected):

1. A new spinal cholinergic pathway regulating baseline blood pressure and acute shock reactions. Sixth Annual Medical Scientist Conference, 1991.
2. Essential hypertension and microsurgical Techniques. Surgery Grand Rounds, Medical College of Georgia, 1992.
3. Alterations in neuro-cardiovascular function in patients with medullary neoplasms. Surgery Grand Rounds, Johns Hopkins Hospital, 1994.
4. "The Intern", Nightline with Ted Koppel, ABC Television, 1996.
5. End-stage Heart Failure and Cardiac Transplantation, Mercer University Medical Center at Savannah Memorial Hospital. Medicine Grand Rounds, 2001.
6. Heart Failure and new Drug Therapies, Brunswick Medical Center. Medicine Grand Rounds, 2001.
7. Hospital Management of Acute Decompensated Heart Failure. Southeastern Arrhythmia Conference. Hilton Head Island, SC 2002.
8. Management of Acute Decompensated Heart Failure Drugs and Device Therapy: Florida Arrhythmia and Heart Failure Update. Ismorada, FL 2002.
9. B-Natriuretic Peptide Improves Hemodynamics and Renal Function in Heart Transplant Patients Immediately After Surgery. International Society of Heart and Lung Transplant, Vienna, 2003.
10. Presentation of MIRACLE Data, and Debate on RBBB and CRT with David Kass. 20th Annual Brazilian Arrhythmia Conference, Rio, 2003.

National/International Moderated Sessions Last Two Years Only:

- * Faculty, International Society of Heart & Lung transplant, San Francisco 2004.
- * Faculty at Heart Rhythm Society, New Orleans 2005
- * Faculty Heart failure Society of America, Boca 2005
- * Faculty American College of Cardiology, Atlanta 2006
- * Faculty at Heart Rhythm Society, Boston 2006
- * Faculty American Academy of Thoracic Surgery, Philadelphia 2006
- * Faculty Heart failure Society of America, Seattle (upcoming 2006)

Over 30 Grand Rounds Presentations in the last two years

Research Support

1. Beta-Adrenergic receptor kinases in heart failure. American Heart Association. Primary Investigator – D. Feldman; Declined (1999).
2. BARK1 function and regulation in heart failure. Howard Hughes Medical Institute. Physician-Scientist grant Primary Investigator – D. Feldman; (estimated total funds \$1, 000, 000) September 1999 through September 2002.
3. Selective Investment Support (OSU) \$160,000/yr for three years Starting 2006-2009. Adrenergic signaling and genomic perturbations in a nonischemic cardiomyopathy.
4. David/Bremer Grant. Primary Investigator – D. Feldman; (estimated total funds \$49, 960), 2006.
5. Mechanisms of the long-term detrimental effects of therapy in the failing heart. Ross Research Funds. Co-Investigator – D. Feldman; (estimated total funds \$100, 000), 2006.
6. Adrenergically mediated remodeling in nonischemic heart failure- D. Feldman PI, *pending application* to NIH (1 RO1 HL084498-01A1).